V viewing financial report ｜*ST Ji medicine is suspected of being filed in violation of the rules. The stock price is almost "cut" during the year

Zhongxin Jingwei, July 27th. *ST Ji Yao announced on the evening of the 27th that due to the illegal information disclosure of information disclosure, the CSRC decided to file a case against the company.

*ST Ji Pharmaceutical said that the company received the CSRC's "Notice of Filing C case" (CSRC No. 02020222003) on July 27, 2022. Because the company was suspected of information disclosure of illegal laws and violations, in accordance with the "Securities Law of the People's Republic of China" and "People's People's People's People's Republic of China" In laws and regulations such as the Republic's Administrative Penalty Law, the CSRC decided to file a case against the company.

*ST Ji Pharmaceutical said that during the investigation of the case, the company will actively cooperate with the investigation of the China Securities Regulatory Commission and strictly perform the obligation of information disclosure in accordance with the supervision requirements.

It is worth mentioning that on July 22, the Management Department of the Shenzhen Stock Exchange's GEM company just issued an inquiry letter under the*ST Ji medicine, requiring the combination of operating cash flow, repayment interest payment, monetary funds, etc. At present, there are risks of fund chain break and fully prompt risks.

On June 30,*ST Ji medicine released the "Annual Report 2021 Annual Report" stated that it achieved operating income of 685 million yuan, an increase of 5.58%year -on -year; net loss attributable to shareholders of listed companies was 451 million yuan, and the loss expanded by 18.67%year -on -year. However, the audit opinion of the China -Public Accounting Firm (Special Ordinary Partnership) on the financial report of the 2021*ST Ji Pharmaceutical is: unable to express their opinions.

*ST Ji Pharmaceutical's official website shows that*ST Ji Pharmaceutical is a listed company in the Shenzhen Stock Exchange. The main business is in the pharmaceutical industry (Chinese and Western Pharmaceutical Production), pharmaceutical commerce (wholesale, agency), medical retail, medical care (medical treatment with medical care Combined elderly care services) such as group -based enterprises with large health industries.

Wind data shows that on July 27,*ST Ji drug closed at 4.53%to 2.32 yuan, a cumulative decrease of 46.42%during the year. (Zhongxin Jingwei APP)

- END -